Venom Antiserum is a medication made from antibodies which is used to treat certain venomous bites and stings. They are recommended only if there is significant toxicity or a high risk of toxicity. The specific Venom Antiserum needed depends on the species involved. It is given by injection.
Snake Venom Antiserum Market contains market size and forecasts of Snake Venom Antiserum in global, including the following market information:
- Global Snake Venom Antiserum Market Revenue, 2017-2022, 2023-2028, ($ millions)
- Global Snake Venom Antiserum Market Sales, 2017-2022, 2023-2028, (K Vials)
Global top five Snake Venom Antiserum companies in 2021 (%)
The global Snake Venom Antiserum market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Polyvalent Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Snake Venom Antiserum include CSL, Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts and Bharat Serums and Vaccines, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Snake Venom Antiserum manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Snake Venom Antiserum Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Vials)
Global Snake Venom Antiserum Market Segment Percentages, by Type, 2021 (%)
Global Snake Venom Antiserum Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Vials)
Global Snake Venom Antiserum Market Segment Percentages, by Application, 2021 (%)
- Hospitals and Clinics
- Non-profit Institutions
Global Snake Venom Antiserum Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Vials)
Global Snake Venom Antiserum Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Snake Venom Antiserum revenues in global market, 2017-2022 (Estimated), ($ millions)
- Key companies Snake Venom Antiserum revenues share in global market, 2021 (%)
- Key companies Snake Venom Antiserum sales in global market, 2017-2022 (Estimated), (K Vials)
- Key companies Snake Venom Antiserum sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- CSL
- Merck
- BTG
- Pfizer
- Haffkine Bio-Pharmaceutical
- Rare Disease Therapeutics
- Flynn Pharma
- Vins Bioproducts
- Bharat Serums and Vaccines
- Serum Biotech
- MicroPharm
Industry Market Size
